Assessing the ability of human endothelial cells derived from induced-pluripotent stem cells to form functional microvasculature in vivo.


Journal

Biotechnology and bioengineering
ISSN: 1097-0290
Titre abrégé: Biotechnol Bioeng
Pays: United States
ID NLM: 7502021

Informations de publication

Date de publication:
02 2019
Historique:
received: 09 05 2018
revised: 22 08 2018
accepted: 07 11 2018
pubmed: 11 11 2018
medline: 3 1 2020
entrez: 11 11 2018
Statut: ppublish

Résumé

Forming functional blood vessel networks is a major clinical challenge in the fields of tissue engineering and therapeutic angiogenesis. Cell-based strategies to promote neovascularization have been widely explored, but cell sourcing remains a significant limitation. Induced-pluripotent stem cell-derived endothelial cells (iPSC-ECs) are a promising, potentially autologous, alternative cell source. However, it is unclear whether iPSC-ECs form the same robust microvasculature in vivo documented for other EC sources. In this study, we utilized a well-established in vivo model, in which ECs (iPSC-EC or human umbilical vein endothelial cells [HUVEC]) were coinjected with normal human lung fibroblasts (NHLFs) and a fibrin matrix into the dorsal flank of severe combined immunodeficiency mice to assess their ability to form functional microvasculature. Qualitatively, iPSC-ECs were capable of vessel formation and perfusion and demonstrated similar vessel morphologies to HUVECs. However, quantitatively, iPSC-ECs exhibited a two-fold reduction in vessel density and a three-fold reduction in the number of perfused vessels compared with HUVECs. Further analysis revealed the presence of collagen-IV and α-smooth muscle actin were significantly lower around iPSC-EC/NHLF vasculature than in HUVEC/NHLF implants, suggesting reduced vessel maturity. Collectively, these results demonstrate the need for increased iPSC-EC maturation for clinical translation to be realized.

Identifiants

pubmed: 30414271
doi: 10.1002/bit.26860
pmc: PMC6322937
mid: NIHMS997442
doi:

Substances chimiques

Fibrin 9001-31-4

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

415-426

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL085339
Pays : United States
Organisme : NIDCR NIH HHS
ID : T32 DE007057
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008353
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM145304
Pays : United States

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Références

Microvasc Res. 1983 Jan;25(1):68-84
pubmed: 6835100
Methodist Debakey Cardiovasc J. 2013 Oct-Dec;9(4):206-9
pubmed: 24298311
J Am Coll Cardiol. 2004 Aug 4;44(3):654-60
pubmed: 15358036
Methodist Debakey Cardiovasc J. 2012 Oct-Dec;8(4):10-4
pubmed: 23342182
PLoS One. 2017 Mar 13;12(3):e0173271
pubmed: 28288160
Tissue Eng. 2006 Oct;12(10):2875-88
pubmed: 17518656
J Tissue Eng Regen Med. 2011 Apr;5(4):e74-86
pubmed: 21413157
J Invest Dermatol. 2007 Mar;127(3):526-37
pubmed: 17299435
Circulation. 2011 Feb 1;123(4):e18-e209
pubmed: 21160056
Circ J. 2004 Dec;68(12):1189-93
pubmed: 15564705
Adv Wound Care (New Rochelle). 2018 Jul 1;7(7):232-246
pubmed: 29984113
Trends Biotechnol. 2008 Aug;26(8):434-41
pubmed: 18585808
Dev Cell. 2015 Jul 6;34(1):5-17
pubmed: 26151903
Circ Res. 2009 Jun 19;104(12):1410-20
pubmed: 19443841
Curr Opin Hematol. 2015 May;22(3):252-7
pubmed: 25767955
Tissue Eng Part A. 2009 Aug;15(8):2039-50
pubmed: 19368510
Blood. 2011 Oct 27;118(17):4740-9
pubmed: 21835951
J Bone Miner Res. 2003 Apr;18(4):696-704
pubmed: 12674330
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Sci Rep. 2018 Feb 8;8(1):2671
pubmed: 29422650
Stem Cell Reports. 2018 May 8;10(5):1642-1656
pubmed: 29657098
Semin Cell Dev Biol. 2011 Dec;22(9):993-1004
pubmed: 21624487
Can J Cardiol. 2009 Jun;25(6):e195-202
pubmed: 19536390
J Cereb Blood Flow Metab. 2014 Jul;34(7):1180-7
pubmed: 24736890
Biophys J. 2008 Mar 1;94(5):1930-41
pubmed: 17993494
Tissue Eng Part A. 2011 Apr;17(7-8):905-14
pubmed: 20979533
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13793-8
pubmed: 22869753
Circ Res. 2008 Jul 18;103(2):194-202
pubmed: 18556575
Angiogenesis. 2012 Jun;15(2):253-64
pubmed: 22382584
Acta Biomater. 2014 Apr;10(4):1515-23
pubmed: 23933102
Tissue Eng Part A. 2013 May;19(9-10):1209-22
pubmed: 23216113
Nature. 2004 Mar 11;428(6979):138-9
pubmed: 15014486
Biomaterials. 2013 Mar;34(8):1995-2004
pubmed: 23245925
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Am J Transl Res. 2013;5(1):21-35
pubmed: 23390563
Biomaterials. 2005 May;26(14):1857-75
pubmed: 15576160
Mol Ther. 2009 Jan;17(1):183-90
pubmed: 18985030
Biomater Sci. 2014 Oct 1;2(10):1497-1508
pubmed: 25177487
Arch Cardiovasc Dis. 2016 Dec;109(12):708-715
pubmed: 27595467
Brain Circ. 2016 Apr-Jun;2(2):104
pubmed: 30276281
Nature. 2000 Sep 14;407(6801):242-8
pubmed: 11001067
Exp Cell Res. 2010 Mar 10;316(5):813-25
pubmed: 20067788
J Histochem Cytochem. 1989 Mar;37(3):315-21
pubmed: 2918221
Blood. 2008 May 1;111(9):4551-8
pubmed: 18256324
Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):e72-9
pubmed: 21836062
Pharm Res. 2010 Feb;27(2):264-71
pubmed: 19953308
Circ Res. 1963 Apr;12:375-8
pubmed: 14000509
Blood. 2012 Aug 16;120(7):1516-27
pubmed: 22740442
Ann Vasc Surg. 2008 Mar;22(2):238-47
pubmed: 18083329
J R Soc Interface. 2006 Oct 22;3(10):589-601
pubmed: 16971328
Tissue Eng Part A. 2010 Feb;16(2):585-94
pubmed: 19737050
Stem Cell Reports. 2013 Jul 25;1(2):105-13
pubmed: 24052946
J Clin Pathol. 2003 Dec;56(12):885-7
pubmed: 14645343

Auteurs

Jonathan R Bezenah (JR)

Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan.

Ana Y Rioja (AY)

Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.

Benjamin Juliar (B)

Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.

Nicole Friend (N)

Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.

Andrew J Putnam (AJ)

Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan.
Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH